Charles River Laboratories International, Inc. (CRL) Holdings Lifted by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,108 shares of the medical research company’s stock after buying an additional 4,150 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.22% of Charles River Laboratories International worth $10,429,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in CRL. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after purchasing an additional 202 shares in the last quarter. Riverhead Capital Management LLC lifted its position in shares of Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares in the last quarter. Cambridge Advisors Inc. purchased a new stake in shares of Charles River Laboratories International in the second quarter worth approximately $202,000. Advisor Partners LLC purchased a new stake in shares of Charles River Laboratories International in the second quarter worth approximately $208,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Charles River Laboratories International in the second quarter worth approximately $217,000. Institutional investors own 95.38% of the company’s stock.

A number of analysts have recently issued reports on CRL shares. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Robert W. Baird reissued a “buy” rating and issued a $114.00 price target on shares of Charles River Laboratories International in a research report on Friday, September 1st. Citigroup Inc. reissued a “neutral” rating and issued a $104.00 price target (up from $91.00) on shares of Charles River Laboratories International in a research report on Wednesday, June 28th. BidaskClub lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $121.00 price target on shares of Charles River Laboratories International in a research report on Friday, June 30th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $100.50.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total transaction of $678,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the transaction, the insider now directly owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,529 shares of company stock valued at $2,278,496. Insiders own 2.20% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) opened at 112.59 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $113.83. The stock has a 50 day moving average of $107.86 and a 200-day moving average of $97.96. The stock has a market capitalization of $5.36 billion, a price-to-earnings ratio of 29.67 and a beta of 0.96.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. During the same quarter in the prior year, the firm posted $1.20 EPS. The business’s revenue was up 8.1% on a year-over-year basis. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Charles River Laboratories International, Inc. (CRL) Holdings Lifted by Parametric Portfolio Associates LLC” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/13/charles-river-laboratories-international-inc-crl-holdings-lifted-by-parametric-portfolio-associates-llc.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply